IP Library › Granted Patent US 9,421,253
Granted Patent B2
US 9,421,253 · App. 13/983,136 · Granted Aug 23, 2016

Compositions for canine respiratory disease complex

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,421,253
App. No.
13/983,136
Granted
Aug 23, 2016
Kind
B2
Abstract

Provided herein are compositions comprising a canine influenza virus and a canine respiratory coronavirus. They can further comprise Bordetella bronchiseptica , pertactin, canine parainfluenza virus, and canine adenovirus serotype 2. The compositions are effective for treating or preventing canine respiratory diseases, including canine infectious respiratory disease complex.

Claims (13)

1. A vaccine composition comprising a canine influenza virus (CIV), canine respiratory coronavirus (CRCoV), and an adjuvant selected from the group consisting of an aluminum hydroxide gel, an oil-in-water emulsion, a water-in-oil emulsion, and a triterpenoid-containing preparation, wherein said CIV is deposited with the ATCC as PTA-7694, and said CRCoV is deposited with the ATCC as PTA-11444.

2. The vaccine composition ref claim 1 , further comprising Bordetella bronchiseptica.

3. The vaccine composition of claim 2 , further comprising a p68 pertactin antigen.

4. The vaccine composition of claim 2 , wherein said Bordetella bronchiseptica is a bacterin or a bacterial extract.

5. The vaccine composition of claim 2 , further comprising a canine parainfluenza virus (CPIV) antigen or canine adenovirus type 2 (CAV-2) antigen.

6. The vaccine composition of claim 5 , wherein the CPIV antigen is CPIV and the CAV-2 antigen is CAV-2.

7. The vaccine composition of claim 2 , wherein said composition is non-adjuvanted.

8. The vaccine composition of claim 1 , wherein said composition does not contain a non-respiratory antigen.

9. The vaccine composition of claim 1 , wherein said composition treats or prevents canine infectious respiratory disease complex (CIRDC) in a canine.

10. A method of treating or preventing CIRDC in a canine comprising administering to said canine the immunogenic composition of claim 1 .

11. The method of claim 10 , wherein said composition prevents CIRDC for a period of about six months or more.

12. The method of claim 10 , wherein said composition prevents CIRDC for a period of about one year.

13. The vaccine composition of claim 1 , wherein administration of said composition to a canine protects said canine against CRCoV infection.

Assignments (2)
ADDRESS CHANGE OF ASSIGNEE Recorded Jun 6, 2017
From: ZOETIS SERVICES LLC
To: ZOETIS SERVICES LLC
Reel/Frame 042698/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: ZOETIS LLC
To: ZOETIS SERVICES LLC
Reel/Frame 035651/0817 →